Get the Stockscreener App
1.26
14.29%
-0.21
After Hours:
1.30
0.04
+3.17%
Inflarx N V stock is traded at $1.26, with a volume of 1.05M.
It is down -14.29% in the last 24 hours and up +51.26% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.47
Open:
$1.5
24h Volume:
1.05M
Relative Volume:
2.09
Market Cap:
$84.59M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.458
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-23.64%
1M Performance:
+51.26%
6M Performance:
+2.44%
1Y Performance:
-12.50%
1-Day Range:
$1.21
$1.51
1-Week Range:
$1.21
$1.77
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.26 | 107.04M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Technical analysis overview for InflaRx N.V. stock2025 Market Overview & Fast Moving Stock Watchlists - Newser
Analyzing drawdowns of InflaRx N.V. with statistical toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser
Price action breakdown for InflaRx N.V.Market Trend Summary & Reliable Volume Spike Trade Alerts - Newser
Best data tools to analyze InflaRx N.V. stockMarket Growth Report & Community Trade Idea Sharing - Newser
InflaRx N.V. recovery potential after sell off2025 Top Decliners & Weekly Return Optimization Plans - Newser
InflaRx Regains Nasdaq Compliance with Share Price Recovery - TipRanks
What momentum shifts mean for InflaRx N.V.July 2025 Price Swings & Community Trade Idea Sharing Platform - Newser
Will InflaRx N.V. price bounce be sustainable2025 Investor Takeaways & Safe Capital Growth Stock Tips - Newser
Pattern recognition hints at InflaRx N.V. upsideDip Buying & Fast Gain Swing Trade Alerts - Newser
Momentum divergence signals in InflaRx N.V. chartJuly 2025 Earnings & Real-Time Sentiment Analysis - Newser
InflaRx regains Nasdaq compliance as shares maintain $1 minimum - Investing.com
InflaRx N.V. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Biotech InflaRx Maintains $1.00+ Share Price for 10 Days, Secures Continued Nasdaq Listing - Stock Titan
Key metrics from InflaRx N.V.’s quarterly dataQuarterly Trade Report & Low Volatility Stock Recommendations - Newser
Multi asset correlation models including InflaRx N.V.Weekly Trading Summary & AI Enhanced Trading Signals - Newser
Will InflaRx N.V. see short term momentumJuly 2025 WrapUp & Entry Point Strategy Guides - Newser
Custom watchlist performance reports with InflaRx N.V. - Newser
Leading vs lagging indicators on InflaRx N.V. performanceWeekly Trade Report & Low Risk High Reward Trade Ideas - Newser
How high can InflaRx N.V. stock goEarnings Risk Summary & Long-Term Safe Return Strategies - Newser
Understanding InflaRx N.V.’s price movementTrade Risk Summary & Fast Exit and Entry Strategy Plans - Newser
Will InflaRx N.V. outperform the marketWeekly Trading Summary & AI Optimized Trade Strategies - Newser
InflaRx N.V. stock volume spike explainedMarket Sentiment Summary & AI Forecast for Swing Trade Picks - Newser
How to read the order book for InflaRx N.V.Bond Market & Community Shared Stock Ideas - Newser
What makes InflaRx N.V. stock price move sharplyCPI Data & Accurate Entry and Exit Point Alerts - Newser
Detecting support and resistance levels for InflaRx N.V.Quarterly Profit Review & Short-Term High Return Ideas - Newser
Will breakout in InflaRx N.V. lead to full recovery2025 Support & Resistance & Risk Managed Investment Strategies - Newser
Q3 Earnings Estimate for InflaRx Issued By HC Wainwright - MarketBeat
Is InflaRx N.V. forming a bottoming base2025 Volume Leaders & High Conviction Investment Ideas - Newser
Technical signs of recovery in InflaRx N.V.Stock Surge & Weekly Sector Rotation Insights - Newser
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):